drugset / Trial / NCT06494878
The PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity
Phase 3
Not yet recruiting
8805 enrolled
University of Calgary
Canadian Institutes of Health Research (CIHR) · collab
RandomizedParallel-groupOpen-labelPrevention
Summary
The goal of the PARTUM trial is to determine if taking low-dose aspirin daily for 6 weeks after delivery is similar (non-inferior) to usual care low-molecular-weight heparin injections to prevent venous thromboembolism (VTE: blood clots in the legs or lungs) for postpartum individuals with VTE risk factors.
Timeline
- Start
- 2025-04
- Primary completion
- 2030-08
- Completion
- 2030-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aspirin | Small molecule | 75 mg | Oral |
| Subject | Aspirin | Small molecule | 100 mg | Oral |
| Subject | Dalteparin sodium | Other / unclassified | — | — |
| Subject | Enoxaparin sodium | Other / unclassified | — | — |
| Subject | Nadroparin Calcium | Other / unclassified | — | — |
| Subject | Tinzaparin | Other / unclassified | — | — |